Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.
Xiaolin Zhang, PhD
Xiaolin Zhang, PhD, is the chief executive officer of Dizal Pharmaceuticals.
Articles by Xiaolin Zhang, PhD
